Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial (Q36612184)

15 August 2017

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial (English)

1 reference

adaptive radiation therapy

15 August 2017

0 references

chemotherapy

1 reference

inferred from title

endometrial carcinoma

1 reference

F Spina

3

0 references

Paolo Zola

object named as

P Zola

5

0 references

author name string

R Maggi

1

1 reference

15 August 2017

A Lissoni

2

1 reference

15 August 2017

M Melpignano

4

1 reference

15 August 2017

G Favalli

6

1 reference

15 August 2017

A Colombo

7

1 reference

15 August 2017

R Fossati

8

1 reference

15 August 2017

language of work or name

English

0 references

publication date

25 July 2006

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

95

1 reference

15 August 2017

3

1 reference

15 August 2017

266-271

1 reference

A note on competing risks in survival data analysis

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Stage I-II endometrial adenocarcinoma evolution of therapeutic paradigms: the role of surgery and adjuvant radiation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360651

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603279

Estimates of the world-wide prevalence of cancer for 25 sites in the adult population

21 January 2018

1 reference

12 December 2020

GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma?

1 reference

12 December 2020

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer

1 reference

12 December 2020

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study

1 reference

12 December 2020

Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide

1 reference

12 December 2020

Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.

1 reference

12 December 2020

Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium

1 reference

12 December 2020

Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients

1 reference

12 December 2020

In vitro studies of Taxol as a radiation sensitizer in human tumor cells

1 reference

12 December 2020

Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol)

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603279

1 reference

OpenCitations bibliographic resource ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

16868539

1 reference